This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Bull of the Day: Halozyme Therapeutics (HALO)
by Kevin Cook
The Street bailed on HALO in the spring, right before a summer rally to new highs on strong growth
HALONegative Net Change
immuno-therapy medical pharmaceuticals
Company News for Sep 23, 2025
by Zacks Equity Research
Companies In The News Are: ORCL, TAP, AAPL, MTSR, PFE.
AAPLNegative Net Change PFEPositive Net Change ORCLNegative Net Change TAPPositive Net Change MTSRNegative Net Change
biotechnology consumer-staples pharmaceuticals tech-stocks
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
by Zacks Equity Research
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
REGNPositive Net Change SNYPositive Net Change CRMDPositive Net Change KNSAPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing
by Zacks Equity Research
The FDA extends SNY's tolebrutinib NDA review by three months, with decision now expected on Dec. 28, 2025.
SNYPositive Net Change CRMDPositive Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?
by Sundeep Ganoria
FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.
MRKPositive Net Change MRNANegative Net Change SMMTPositive Net Change
biotechs medical pharmaceuticals vaccines
J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?
by Kinjel Shah
J&J shares gain 17.7% in three months, adding $63B to its market cap. Technical and pipeline momentum fuel investor interest.
JNJPositive Net Change AMGNPositive Net Change TEVANegative Net Change
pharmaceuticals
Take the Zacks Approach to Beat the Market: LendingTree, AutoZone, J&J in Focus
by Abhinab Dasgupta
Zacks highlights winners like LendingTree, AutoZone, and Johnson & Johnson as its proven stock-picking strategies continue to shine.
GSPositive Net Change JNJPositive Net Change TSCOPositive Net Change SJMPositive Net Change AZOPositive Net Change TREEPositive Net Change COMMNegative Net Change NTLANegative Net Change MEDPPositive Net Change PLTRNegative Net Change HOODNegative Net Change
auto-tires-trucks finance pharmaceuticals
Top Research Reports for Costco, Morgan Stanley & Caterpillar
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), Morgan Stanley (MS), and Caterpillar Inc. (CAT).
MSPositive Net Change CATPositive Net Change AMGNPositive Net Change COSTNegative Net Change CRWDPositive Net Change SONYNegative Net Change
finance pharmaceuticals tech-stocks
Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?
by Zacks Equity Research
Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.
AZNPositive Net Change JNJPositive Net Change MRKPositive Net Change UTHRPositive Net Change
pharmaceuticals
Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?
by Zacks Equity Research
NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?
by Ekta Bagri
Bristol Myers ramps up a $2.5B restructuring plan to cut costs, streamline operations, and offset pressure from generic competition.
BMYPositive Net Change NVONegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
by Zacks Equity Research
Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.
NVSPositive Net Change QGENNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights AbbVie, ServiceNow, Boeing, Tucows and and Ampco-Pittsburgh
by Zacks Equity Research
Zacks spotlights AbbVie, ServiceNow, Boeing, Tucows, and Ampco-Pittsburgh, detailing growth drivers, headwinds, and industry positioning.
BAPositive Net Change TCXPositive Net Change APNegative Net Change ABBVPositive Net Change NOWPositive Net Change
aerospace computers internet-content medical-devices pharmaceuticals
PFE vs. AZN: Which Cancer-Focused Drug Giant Is the Better Pick?
by Kinjel Shah
AstraZeneca and Pfizer both boast strong oncology pipelines, but growth paths, dividends and challenges set them apart for investors.
AZNPositive Net Change PFEPositive Net Change
pharmaceuticals
Top Wide-Moat Stocks Worth a Look for Sustainable Growth
by Anindya Barman
MSFT, JNJ, NKE and SPGI use strong moats to fend off rivals and deliver consistent returns amid market shifts.
AMZNPositive Net Change MSFTPositive Net Change NKEPositive Net Change JNJPositive Net Change URBNPositive Net Change SPGIPositive Net Change KVUEPositive Net Change
cloud-computing consumer-discretionary finance medical pharmaceuticals
Top Analyst Reports for AbbVie, ServiceNow & Boeing
by Mark Vickery
AbbVie, ServiceNow, and Boeing outpace their industries as analysts highlight growth drivers and risks in fresh research reports.
BAPositive Net Change AMXPositive Net Change UBSPositive Net Change TCXPositive Net Change IDXXPositive Net Change APNegative Net Change ABBVPositive Net Change NOWPositive Net Change
aerospace computers internet-content medical-devices pharmaceuticals
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
by Zacks Equity Research
Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline.
GSKPositive Net Change NVSPositive Net Change RHHBYNegative Net Change ETNBNo Net Change
biotechnology biotechs medical pharmaceuticals
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
by Ekta Bagri
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
ILMNNegative Net Change BEAMNegative Net Change WVEPositive Net Change CRSPPositive Net Change TWSTPositive Net Change WGSPositive Net Change
biotechnology biotechs gene-editing genetics genomics medical pharmaceuticals
J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why
by Kinjel Shah
J&J sees Innovative Medicines growth in 2025, fueled by oncology and immunology drugs, despite steep Stelara sales erosion.
AZNPositive Net Change JNJPositive Net Change AMGNPositive Net Change ABBVPositive Net Change
pharmaceuticals
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?
by Zacks Equity Research
Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?
by Ahan Chakraborty
CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.
PFEPositive Net Change AMPHPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biogen Gets EU Nod for First Postpartum Depression Drug
by Zacks Equity Research
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
BIIBPositive Net Change SUPNNegative Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechs medical pharmaceuticals
LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?
by Kinjel Shah
Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.
AZNPositive Net Change GSKPositive Net Change JNJPositive Net Change LLYPositive Net Change
pharmaceuticals
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
by Zacks Equity Research
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
INCY Announces New Late-Stage Data on Skin Disease Drug
by Zacks Equity Research
Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.
NVSPositive Net Change INCYPositive Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals